Department of Intensive Care Unit, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, 269 University Road, Xuzhou 221000, Jiangsu, China.
Department of Anesthesiology, The First People's Hospital of Lianyungang, 182 Tongguan Road, Lianyungang 222000, Jiangsu, China.
Contrast Media Mol Imaging. 2022 May 28;2022:7884508. doi: 10.1155/2022/7884508. eCollection 2022.
A case-control study was conducted to evaluate the efficacy of continuous veno-venous hemofiltration (CVVH) combined with Xuebijing in the treatment of severe sepsis. In order to verify this claim, this study included 100 patients with severe sepsis treated in our hospital from February 2019 to April 2021. The patients were randomly divided into control group and study group. The control group was treated with CVVH, and the study group was treated with CVVH combined with Xuebijing. The curative effect and mortality, NT-proBNP, PCT, Ca∼_(2+), white blood cell count, neutrophil ratio, blood gas analysis, and APACHE-II score were compared between the two groups. The total effective rate of the study group was better than that of the control group ( < 0.05). The fatality rate in the study group was lower than that in the control group ( < 0.05). The levels of NT-proBNP and PCT in the study group were lower than those in the control group, while the level of serum calcium in the study group was higher than that in the control group. After treatment, the white blood cell count (WBC) and neutrophil count in the study group were (13.76 ± 1.28) × 109 shock L and (73.48 ± 1.23)%, respectively, which were significantly lower than those in the control group (17.45 ± 1.36) × 109 shock L and (77.82 ± 1.44)% ( < 0.05). After treatment, the levels of APTT, PT, and DD in the study group were lower than those in the control group. The level of FIB in the study group was significantly higher than that in the control group after treatment. After treatment, the PaO and PaO/FiO of the study group were higher than those of the control group, and the APACHE-II score of the study group was lower than that of the control group. CVVH combined with Xuebijing is of positive significance in the treatment of severe sepsis and is worth popularizing.
一项病例对照研究旨在评估连续静脉-静脉血液滤过（CVVH）联合血必净治疗严重脓毒症的疗效。为了验证这一说法，本研究纳入了 2019 年 2 月至 2021 年 4 月在我院接受治疗的 100 例严重脓毒症患者。患者被随机分为对照组和研究组。对照组采用 CVVH 治疗，研究组采用 CVVH 联合血必净治疗。比较两组患者的疗效和死亡率、NT-proBNP、PCT、Ca∼_(2+)、白细胞计数、中性粒细胞比例、血气分析和 APACHE-II 评分。研究组总有效率优于对照组（<0.05）。研究组死亡率低于对照组（<0.05）。研究组 NT-proBNP 和 PCT 水平低于对照组，血清钙水平高于对照组。治疗后，研究组白细胞计数（WBC）和中性粒细胞计数分别为（13.76±1.28）×109/L 和（73.48±1.23）%，显著低于对照组的（17.45±1.36）×109/L 和（77.82±1.44）%（<0.05）。治疗后，研究组 APTT、PT 和 DD 水平低于对照组。治疗后，研究组 FIB 水平显著高于对照组。治疗后，研究组 PaO 和 PaO/FiO 高于对照组，APACHE-II 评分低于对照组。CVVH 联合血必净治疗严重脓毒症具有积极意义，值得推广。
